Credit Suisse Maintains Outperform on United Therapeutics, Raises Price Target to $247
Credit Suisse analyst Tiago Fauth maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $219 to $247.
UPDATE: FDA Doc For United Therapeutics, MannKind Lung Disease Therapy (Link In Body Of This Headline)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214324s000lbl.pdf
United Therapeutics Q1 EPS $5.03 Beats $3.34 Estimate, Sales $461.90M Beat $420.02M Estimate
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $5.03 per share which beat the analyst consensus estimate of $3.34 by 50.6 percent. This is a 44.13 percent increase over earnings of $3.49 per share from
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Earnings Outlook For United Therapeutics
United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $3.34.
JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $223
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $230 to $223.
First Human With Pig Heart Transplant Dies
A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig’s heart…
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
Ferrer
BARCELONA, Spain - February 28, 2022 - (Newswire.com)
In the run up to Rare Disease Day, which is held on 28 February, International pharmaceutical company Ferrer has strengthened its focus on
BTIG Initiates Coverage On United Therapeutics with Neutral Rating
BTIG analyst Julian Harrison initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Neutral rating.
United Therapeutics Outlines Achievements Of Its Xenotransplantation Programs
UKidney™ procedure data published in the American Journal of Transplantation; the first such data published in a peer-reviewed journal
UHeart™ recipient patient reaches a two-week milestone